APA (7th ed.) Citation

Eron, J. J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., . . . Yeo, J. (2013). Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. The Journal of infectious diseases, 207(5), 740-748. https://doi.org/10.1093/infdis/jis750

Chicago Style (17th ed.) Citation

Eron, Joseph J., et al. "Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study." The Journal of Infectious Diseases 207, no. 5 (2013): 740-748. https://doi.org/10.1093/infdis/jis750.

MLA (9th ed.) Citation

Eron, Joseph J., et al. "Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study." The Journal of Infectious Diseases, vol. 207, no. 5, 2013, pp. 740-748, https://doi.org/10.1093/infdis/jis750.